Treats HER2-overexpressing breast cancer. Sold as Herceptin. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Trastuzumab (sold as Herceptin), first approved Sep 25, 1998, with 9 new uses approved and 0 published complete response letters.
| Herceptin | Part B | $69.6M | -25% | 2,357 |
| Herceptin | Part D | $5.0M | +7% | 142 |
| A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer · Centre Leon Berard | Phase 2 | Not yet recruiting | Nov 13, 2026 |
| Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBCBreast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer · Harbin Medical University | Phase 2 | Not yet recruiting | Nov 13, 2026 |
| Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 StudyHER2-positive Breast Cancer, Early Breast Cancer (EBC) · The Netherlands Cancer Institute | Phase 1 | Not yet recruiting | Nov 10, 2026 |
| Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF MutationColorectal Cancer · Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Nov 9, 2026 |
| 3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer TherapyCancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer · Region Skane | — | Recruiting | Nov 4, 2026 |
| Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJGastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma · Fudan University | Phase 2 | Not yet recruiting | Nov 3, 2026 |
| A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted ImmunochemotherapyGastric Cancer · Samsung Medical Center | Phase 2 | Recruiting | Nov 2, 2026 |
| Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Breast Cancer (Advanced/Metastatic) · Azienda Ospedaliero-Universitaria Careggi | Phase 2 | Not yet recruiting | Oct 29, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA